Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-Gastric/Gastroesophageal Junction Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05218148
What this trial is testing

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Who this might be right for
HER2-positiveLocally Advanced Solid TumorImmunotherapy+4 more
Aiping Zhou 44
Testing effectiveness (Phase 2)UnknownNCT05216237
What this trial is testing

Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer

Who this might be right for
Gastric CancerChemotherapyImmunotherapy
Jiuda Zhao 31
Testing effectiveness (Phase 2)Looking for participantsNCT05969860
What this trial is testing

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Who this might be right for
Advanced Anal CarcinomaAdvanced Biliary Tract CarcinomaAdvanced Bladder Carcinoma+41 more
Mayo Clinic 220
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine 156
Testing effectiveness (Phase 2)Study completedNCT01614522
What this trial is testing

A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2

Who this might be right for
Stomach NeoplasmsCancer of StomachCancer of the Stomach+2 more
ASLAN Pharmaceuticals 24
Not applicableStudy completedNCT05606094
What this trial is testing

Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia

Who this might be right for
Gastric Cancer
Daiichi Sankyo Co., Ltd. 450
Post-approval studies (Phase 4)Not Yet RecruitingNCT07502027
What this trial is testing

A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer (Diagnosis)Gastric Cancer (GC)Gastroesophageal Junction Adenocarcinoma
Huazhong University of Science and Technology 55
Large-scale testing (Phase 3)WithdrawnNCT04859582
What this trial is testing

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension

Who this might be right for
Stomach Neoplasms
Merck Sharp & Dohme LLC
Very early researchEnrolling By InvitationNCT07356466
What this trial is testing

Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric (Stomach) Cancer
Fujian Medical University 100
Testing effectiveness (Phase 2)Ended earlyNCT04727151
What this trial is testing

TAC T-cells for the Treatment of HER2-positive Solid Tumors

Who this might be right for
HER2 Positive Gastric CancerMetastatic HER2 Positive Gastroesophageal Junction Cancer
Triumvira Immunologics, Inc. 28
Testing effectiveness (Phase 2)Ended earlyNCT01123473
What this trial is testing

Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionGastric Cancer
European Organisation for Research and Treatment of Cancer - EORTC 29
Testing effectiveness (Phase 2)Ended earlyNCT02726399
What this trial is testing

Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Memorial Sloan Kettering Cancer Center 7
Testing effectiveness (Phase 2)Study completedNCT02004769
What this trial is testing

Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer

Who this might be right for
Stomach NeoplasmsNeoplasms MetastasisERBB2 Gene Amplification
Sun Yat-sen University 67
Early research (Phase 1)UnknownNCT05315830
What this trial is testing

HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric

Who this might be right for
Adenocarcinoma - GEJAdenocarcinoma of the Stomach
The First Affiliated Hospital of Bengbu Medical University 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT06256328
What this trial is testing

Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Who this might be right for
Gastric Cancer
Ono Pharmaceutical Co., Ltd. 226
Testing effectiveness (Phase 2)Study completedNCT04014075
What this trial is testing

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Who this might be right for
Adenocarcinoma Gastric Stage IV With MetastasesAdenocarcinoma - GEJ
Daiichi Sankyo 79
Large-scale testing (Phase 3)Study completedNCT01774786
What this trial is testing

Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 780
Testing effectiveness (Phase 2)Ended earlyNCT05555251
What this trial is testing

BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Metastatic Breast Cancer+2 more
BioInvent International AB 18
Testing effectiveness (Phase 2)Study completedNCT04661150
What this trial is testing

Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Hoffmann-La Roche 42
Large-scale testing (Phase 3)Looking for participantsNCT06901531
What this trial is testing

Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Next Page
500